DE60132301D1 - Verwendung der extrazellulären Domäne von TRADE Molekülen in Medikamenten zur Behandlung von Neoplasie - Google Patents

Verwendung der extrazellulären Domäne von TRADE Molekülen in Medikamenten zur Behandlung von Neoplasie

Info

Publication number
DE60132301D1
DE60132301D1 DE60132301T DE60132301T DE60132301D1 DE 60132301 D1 DE60132301 D1 DE 60132301D1 DE 60132301 T DE60132301 T DE 60132301T DE 60132301 T DE60132301 T DE 60132301T DE 60132301 D1 DE60132301 D1 DE 60132301D1
Authority
DE
Germany
Prior art keywords
neoplasia
drugs
treatment
extracellular domain
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60132301T
Other languages
English (en)
Inventor
Clive Wood
Divya Chaudhary
Andrew Long
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Application granted granted Critical
Publication of DE60132301D1 publication Critical patent/DE60132301D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60132301T 2000-02-11 2001-02-09 Verwendung der extrazellulären Domäne von TRADE Molekülen in Medikamenten zur Behandlung von Neoplasie Expired - Lifetime DE60132301D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18192200P 2000-02-11 2000-02-11
US18214800P 2000-02-14 2000-02-14
PCT/US2001/004238 WO2001058954A2 (en) 2000-02-11 2001-02-09 Trade molecules and uses related thereto

Publications (1)

Publication Number Publication Date
DE60132301D1 true DE60132301D1 (de) 2008-02-21

Family

ID=26877635

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60132301T Expired - Lifetime DE60132301D1 (de) 2000-02-11 2001-02-09 Verwendung der extrazellulären Domäne von TRADE Molekülen in Medikamenten zur Behandlung von Neoplasie

Country Status (11)

Country Link
US (1) US20020068696A1 (de)
EP (1) EP1254176B1 (de)
JP (1) JP2004501604A (de)
AT (1) ATE383374T1 (de)
AU (1) AU784383B2 (de)
BR (1) BR0108187A (de)
CA (1) CA2399391A1 (de)
DE (1) DE60132301D1 (de)
MX (1) MXPA02007787A (de)
NZ (1) NZ520598A (de)
WO (1) WO2001058954A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837606T2 (de) 1997-09-12 2008-02-14 Biogen Idec Ma Inc., Cambridge Cystein-reiche rezeptoren-train
US7985553B2 (en) * 2001-10-29 2011-07-26 Nathaniel Heintz Method for isolating cell type-specific mRNAs
CN101014245A (zh) 2004-08-03 2007-08-08 比奥根艾迪克Ma公司 神经元功能中的taj
US20070186296A1 (en) * 2006-02-02 2007-08-09 Wyeth Cloning, characterization, and application of tnfrsf19 in neurological disorders
US7888044B2 (en) 2006-04-10 2011-02-15 Trustees Of Boston University Melanoma biomarker and methods of uses
JP5670755B2 (ja) 2008-03-12 2015-02-18 ザ ロックフェラー ユニバーシティ 翻訳プロファイリング及び分子表現型解析のための方法及び組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
ATE321855T1 (de) * 1997-01-14 2006-04-15 Human Genome Sciences Inc Tumor-nekrose-faktor rezeptor 5
KR20000075749A (ko) * 1997-02-27 2000-12-26 오노 야꾸힝 고교 가부시키가이샤 신규의 폴리펩티드, 그 폴리펩티드를 암호하는 ｄｎａ 및 그용도
CA2285040C (en) * 1997-03-17 2009-01-27 Human Genome Sciences, Inc. Death domain containing receptor 5
CA2287911C (en) * 1997-05-15 2014-05-06 Genentech, Inc. Apo-2 receptor
WO1999011791A2 (en) * 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
DE69837606T2 (de) * 1997-09-12 2008-02-14 Biogen Idec Ma Inc., Cambridge Cystein-reiche rezeptoren-train

Also Published As

Publication number Publication date
WO2001058954A3 (en) 2002-03-21
CA2399391A1 (en) 2001-08-16
WO2001058954A9 (en) 2003-01-16
EP1254176A2 (de) 2002-11-06
US20020068696A1 (en) 2002-06-06
AU784383B2 (en) 2006-03-23
EP1254176B1 (de) 2008-01-09
WO2001058954A2 (en) 2001-08-16
AU3683201A (en) 2001-08-20
NZ520598A (en) 2004-04-30
MXPA02007787A (es) 2004-09-10
JP2004501604A (ja) 2004-01-22
BR0108187A (pt) 2005-04-05
ATE383374T1 (de) 2008-01-15

Similar Documents

Publication Publication Date Title
ATE413386T1 (de) Ppar-gamma modulatoren
DE60118544D1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
DE59609235D1 (de) Verwendung von aerogelen in der landwirtschaft
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
MXPA05006043A (es) Polipeptidos terapeuticos, homologos de los mismos, fragmentos de los mismos y para uso al modular la agregacion mediada de plaquetas.
DE69805202T2 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
PL377553A1 (pl) Peptydy oraz pokrewne cząsteczki modulujące aktywność czynnika wzrostu nerwów
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE249220T1 (de) Verwendung von piperin und derivate davon zur behandlung von hautpigmentierungstörungen und hautkrebs
ATE275400T1 (de) Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ
ATE352639T1 (de) Antisense modulation der expression von integrin alpha 4
DE69228997T2 (de) Menschliche il-3-varianten
DE69711078T2 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
DE60327936D1 (de) Modulatoren von ship-1
DE60132301D1 (de) Verwendung der extrazellulären Domäne von TRADE Molekülen in Medikamenten zur Behandlung von Neoplasie
MXPA05009743A (es) Composiciones con actividad hematopoyetica e inmune.
ATE190839T1 (de) Verwendung von prodelphidinen zur behandlung von arthrose
ATE281165T1 (de) Verwendung von pramipexol zur behandlung von restless-legs-syndrom
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung
ATE349521T1 (de) Mit cd40 und traf interagierende proteine
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
DE50200757D1 (de) Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren
ATE344011T1 (de) Verwendung von betain in der haarpflege

Legal Events

Date Code Title Description
8332 No legal effect for de